NCT04338243 - Glumetinib Combined With Osimertinib in the Treatment of Relapsed and Metastatic Non-small Cell Lung Cancer Patients Who Failed to Receive EGFR Inhibitors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 18, 2019

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions

Negative T790M Mutation and Met Amplification

Interventions

DRUG

Glumetinib

Phase Ib is a dose escalation study, the initial dose of Glumetinib is 300mg, then will be escalated to 400mg，according to the result of Phase Ib， will confirm the RP2D

Trial Locations (1)

100000

RECRUITING

Beijing Cancer Hospital, Beijing